目的 设计、构建与表达靶向CD20和HLA-DR分子的crossmab双特异性抗体。方法 设计靶向CD20和HLA-DR分子的crossmab双特异性抗体分子，命名为CD20-HLA-DR CrossmabCH1-CL，利用基因工程技术构建Crossmab四条链的真核表达载体，然后利用FreeStyle 293-F Cells哺乳动物细胞表达体系表达CD20-HLA-DR CrossmabCH1-CL。结果 获得了CD20-HLA-DR CrossmabCH1-CL抗体分子蛋白。结论 成功设计、构建、表达并初步鉴定了靶向CD20和HLA-DR分子的双特异性抗体CD20-HLA-DR CrossmabCH1-CL，为研制新型抗肿瘤的双特异性抗体药物打下了基础。

Objective To design, construct and express the Crossmab bispecific antibody molecular for targeting CD20 and HLA-DR. Methods The Crossmab bispecific antibody was designed, naming CD20-HLA-DR CrossmabCH1-CL, and two light chains and two heavy chains of the Crossmab were constructed by using genetic engineering technology. The constructed two heavy chain expression vectors and two light chain expression vectors were then co-transfected in FreeStyle 293-F cells and the Crossmab protein was expressed. Result The bispecific antibody protein moleculer CD20-HLA-DR CrossmabCH1-CL was obtained. Conclusion CD20-HLA-DR CrossmabCH1-CL targeting on CD20 and HLA-DR is successfully designed, constructed, expressed and characterized and laid the foundation for developing newly anti-tumor therapeutic bispecific antibody.